The association between SGLT2 inhibitors and new-onset arrhythmias: a nationwide population-based longitudinal cohort study

Table 2 Incidence of study events in population between SGLT2 inhibitor group and non- SGLT2 inhibitor group

	Non-SGLT2i		SGLT2i		cHR	aHR
	Pm	Events	Pm	Events	cHR	aHR
All-cause death	733,896	666	742,390	380	0.564 (0.497–0.640)	0.547 (0.482–0.621)
NOA	728,545	858	737,979	721	0.832 (0.754–0.919)	0.830 (0.751–0.916)
Atrial fibrillation	733,017	146	741,713	125	0.849 (0.668–1.077)	0.841 (0.662–1.068)
Supraventricular arrhythmias	733,479	67	742,054	54	0.799 (0.558–1.143)	0.815 (0.570–1.167)
Ventricular arrhythmias	733,651	50	742,207	41	0.813 (0.538–1.229)	0.797 (0.525–1.208)

aHR, controlled for age, sex, comorbidities, and concurrent medications
Supraventricular arrhythmias include atrial premature complexes and paroxysmal supraventricular tachycardia; ventricular arrhythmias include ventricular tachycardia, ventricular fibrillation and ventricular premature complexes
SGLT2i sodium–glucose co-transporter 2 inhibitor, Pm Person-months, cHR crude hazard ratio, aHR adjusted hazard ratio, NOA new-onset arrhythmias

ISSN: 1475-2840